Boehringer Ingelheim

News

GSK et al file appeal to Delaware Zantac order

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead.

News

Boehringer, Lilly face off in MASH at EASL

Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa

News

Boehringer raises hope of diabetic macular ischaemia therapy

Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet

News

Boehringer will use Walgreens trials unit for obesity trial

Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim.

News

Boehringer says R&D pipeline is the best in its long history

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that

News

Jardiance doesn’t cut it in post-heart attack trial

SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients h

GSK et al file appeal to Delaware Zantac order

Boehringer, Lilly face off in MASH at EASL

Boehringer raises hope of diabetic macular ischaemia therapy

Boehringer will use Walgreens trials unit for obesity trial

Boehringer says R&D pipeline is the best in its long history

Jardiance doesn’t cut it in post-heart attack trial

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

Boehringer Ingelheim

Editor's Picks